News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
107last 24h
3127last 7d
512● bullish (7d)
311● bearish (7d)
227publishers
Motley Fool1d agobullish
Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?MT Newswires4d agoneutral
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $620 From $608GuruFocus.com4d agoneutral
Vertex Pharmaceuticals Inc (VRTX) Q3 2026 Earnings Call Highlights: Revenue Up 12% as CF, ...Investing.com5d agoneutral
Vertex Pharmaceuticals earnings analysis: questions answered and next catalystsInvestor's Business Daily5d agobearish
Vertex Slumps On Light Pain Drug Sales, But A Key Kidney Catalyst Lies AheadMT Newswires5d agoneutral
Vertex Stock May See Further Appreciation on Approval, Launch of Povetacicept, RBC SaysMT Newswires5d agobullish
UBS Adjusts Price Target on Vertex Pharmaceuticals to $640 From $615, Maintains Buy RatingMT Newswires5d agobullish
RBC Raises Price Target on Vertex Pharmaceuticals to $600 From $576, Keeps Outperform RatingMT Newswires5d agoneutral
Stifel Adjusts Price Target on Vertex Pharmaceuticals to $563 From $500MT Newswires5d agoneutral
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $660 From $665MT Newswires5d agoneutral
Scotiabank Adjusts Price Target on Vertex Pharmaceuticals to $660 From $558MT Newswires5d agoneutral
Cantor Fitzgerald Adjusts Price Target on Vertex Pharmaceuticals to $619 From $595MT Newswires5d agoneutral
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $725 From $654MT Newswires5d agoneutral
Barclays Adjusts Price Target on Vertex Pharmaceuticals to $626 From $617Simply Wall St.5d agoneutral
Should Strong Q3 Revenue Require Action From Vertex Pharmaceuticals (VRTX) Investors?MT Newswires5d agoneutral
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $650 From $550